101 HCC Risk Factors Ranked: What Truly Drives Liver Cancer Risk
A sweeping umbrella review of 175 meta-analyses grades the evidence behind 101 hepatocellular carcinoma risk factors, from viral hepatitis to statins.
Summary
This umbrella review synthesized 175 meta-analyses to evaluate 101 risk factors for hepatocellular carcinoma (HCC). Of these, 73 reached statistical significance and 31 were classified as Class I, II, or III evidence. HBV and HCV infections emerged as the dominant risk factors, increasing HCC risk 12.5-fold and 11.2-fold respectively. Antiviral treatment reduces these risks substantially. Modifiable lifestyle factors—smoking, obesity, alcohol, and NAFLD—significantly elevate risk, while coffee consumption, healthy diet, and bariatric surgery are protective. Several medications including metformin, GLP-1 receptor agonists, aspirin, statins, and SSRIs were associated with reduced HCC risk, whereas proton pump inhibitors elevated it. Blood type O conferred modest protection, while male sex and older age increased risk.
Detailed Summary
Hepatocellular carcinoma accounts for roughly 90% of primary liver cancers and is projected to cause 1.3 million deaths annually by 2040. Despite abundant individual meta-analyses, no comprehensive synthesis had graded the quality and strength of evidence across the full spectrum of HCC risk factors—until now.
Researchers conducted a PROSPERO-registered umbrella review (CRD42023454708) searching PubMed, EMBASE, Web of Science, and the Cochrane Database through December 2024. From an initial pool of 10,684 articles, 175 meta-analyses were included covering 101 distinct risk factors. Evidence strength was graded using a five-tier classification (Class I–IV plus non-significant) based on case counts, p-value thresholds, heterogeneity (I²), prediction intervals, and publication bias assessed via Egger's test. Methodological quality was evaluated with the AMSTAR tool.
Only 31 of 101 risk factors (30.7%) achieved Class I, II, or III evidence status—a finding that underscores how much of the published literature on HCC risk remains methodologically weak. HBV infection carried the largest effect size (RR ~12.5-fold), followed closely by HCV (RR ~11.2-fold). Within the viral hepatitis category, antiviral treatment and sustained virological response substantially mitigated risk, while higher HBsAg levels, anti-HBc positivity, and HBV/HCV co-infection amplified it. Eight of the 31 high-confidence risk factors were directly tied to viral hepatitis biology.
Among modifiable non-viral factors, smoking, alcohol consumption, obesity, NAFLD, type 2 diabetes, low platelet count, elevated liver enzymes, and liver fluke infection all demonstrated meaningful risk elevation with at least suggestive evidence. Conversely, coffee consumption, adherence to a healthy dietary pattern, and bariatric surgery were associated with reduced HCC incidence. On the pharmacological side, metformin, GLP-1 receptor agonists, aspirin, statins, and selective serotonin reuptake inhibitors (SSRIs) were linked to lower HCC risk, while acid-suppressive agents—particularly proton pump inhibitors—were associated with elevated risk. Non-modifiable factors with robust evidence included male sex, older age, and blood type (type O conferring reduced risk).
The findings carry clear preventive implications: HBV vaccination and antiviral therapies remain the highest-yield interventions globally, but the rising burden in Western nations driven by obesity and metabolic syndrome demands equal attention to lifestyle modification. The potential chemopreventive roles of common drugs like statins, aspirin, and metformin are promising but require confirmatory randomized trial data before clinical recommendations can be made.
Key Findings
- HBV and HCV infections increase HCC risk ~12.5-fold and ~11.2-fold respectively; antiviral therapy substantially reduces this risk.
- Only 31 of 101 studied risk factors (30.7%) reached Class I, II, or III evidence strength.
- Metformin, GLP-1 RAs, aspirin, statins, and SSRIs were associated with reduced HCC risk; proton pump inhibitors elevated it.
- Smoking, obesity, NAFLD, diabetes, alcohol, and liver fluke infection all showed meaningful HCC risk elevation.
- Coffee consumption, healthy diet, bariatric surgery, and blood type O were associated with lower HCC incidence.
Methodology
This is an umbrella review of 175 systematic reviews and meta-analyses identified across four major databases through December 2024. Evidence strength was graded using a five-class criteria system incorporating case numbers, p-value thresholds (including p<10⁻⁶ for Class I/II), I² heterogeneity, prediction intervals, and Egger's test for publication bias. Methodological quality of included meta-analyses was assessed using the AMSTAR tool.
Study Limitations
As an umbrella review, findings inherit the limitations of underlying meta-analyses, including heterogeneity in study populations, variable adjustment for confounders, and potential publication bias across the primary literature. Many risk factor associations (69.3%) only reached Class IV or non-significant evidence, limiting actionable conclusions. Causal directionality cannot be established for observational associations, and pharmacological findings require validation in randomized trials.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.